Compare CleanSpark Inc (CLSK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CleanSpark Inc vs Viatris Inc — how do they compare? CleanSpark Inc trades at $12.19 (market cap $2.96B), while Viatris Inc trades at $16.21 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 6.3× CleanSpark Inc's market cap, and Viatris Inc pays a 2.95% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| CLSK | VTRS | |
|---|---|---|
Market Cap | $2.96B | $18.69B |
Sector | Technology | Health |
52-Week High | $23.20 | $17.86 |
52-Week Low | $8.18 | $9.49 |
Enterprise Value | $3.95B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CleanSpark (CLSK) trades at $12.08, up 4.23% today but facing bearish technical signals with recent earnings misses. The company reported a Q3 2026 loss of $0.89 per share versus expectations of -$0.47, continuing a trend of negative profitability despite securing a significant $6.6 billion AI data center lease. Analyst sentiment remains strongly bullish with 11 buy ratings and a $24.13 consensus price target, representing 100% upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong institutional support but significant execution challenges. While the AI infrastructure pivot offers long-term growth potential, near-term profitability concerns and negative cash flow create substantial volatility. Investors must weigh the disconnect between bullish analyst coverage and persistent earnings underperformance against the company's strategic repositioning in digital infrastructure.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
